Health Technology Assessment, often called HTA, is a structured process used to evaluate the value of a health technology. This may include a medicine, medical device, diagnostic test, digital health solution or healthcare intervention.
The purpose of HTA is to help decision-makers understand whether a technology should be adopted, funded or reimbursed within a healthcare system.
Rather than looking only at whether a technology works, HTA considers its broader value. It looks at clinical benefits, safety, cost-effectiveness, budget impact, quality of life and the needs of patients and healthcare systems.
In simple terms, HTA helps answer an important question:
Does this technology bring enough value to justify its use and funding?
Why is HTA important?
Healthcare systems need to make difficult decisions about how to allocate limited resources. New technologies can bring meaningful benefits, but they also need to be assessed carefully.
HTA provides an evidence-based framework for these decisions. It helps compare a new technology with existing alternatives and shows whether the expected benefits are aligned with the investment required.
For healthcare companies, HTA is especially important because it can influence pricing, reimbursement and access to the market.
A strong HTA strategy can help demonstrate value clearly and support discussions with payers, reimbursement bodies and HTA agencies.
How does HTA support market access?
Market access is the process of ensuring that a health technology reaches the right patients, under the right conditions, and within the right healthcare system.
A good HTA approach can also help identify evidence gaps early. For example, a company may need stronger comparative data, local epidemiology, real-world evidence or clearer economic modelling before submitting to an HTA agency.
It helps companies understand what decision-makers will expect, what evidence may be missing and how the value of the technology should be communicated.
What evidence is used in HTA?
The type of evidence required depends on the technology, country and assessment body. However, most HTA processes consider clinical and economic evidence together.
This may include clinical trial results, safety data, comparison with the current standard of care, cost-effectiveness analysis, budget impact, quality of life outcomes and real-world evidence.
The goal is not only to collect data, but to explain what that data means for patients, payers and healthcare systems.
Final thoughts
Health Technology Assessment plays a key role in modern healthcare decision-making. It helps determine whether new technologies offer meaningful value and whether they should be adopted, reimbursed or prioritised.
At Clevidence, we support organisations across the HTA and market access journey, including evidence gap analysis, therapeutic positioning, value dossiers, reimbursement submissions and local adaptation.